Lumbar Stabilization Exercises in Sedentary Adults

March 2, 2026 updated by: Dimitra Korda, University of West Attica

The Effect of a Lumbar Stabilization Exercise Program on Quality of Life and Motor Control in Sedentary Adults

This pilot randomized controlled trial will examine the effects of a four-week lumbar spine stabilization exercise program on motor control, dynamic balance, and quality of life in healthy sedentary adults. Prolonged sedentary behavior has been associated with impaired neuromuscular function and increased risk of musculoskeletal disorders, even in asymptomatic individuals.

Forty sedentary adults will be randomly assigned to either an intervention group, which will follow a structured lumbar stabilization exercise program, or to a control group, which will receive ergonomic and stretching guidelines.

Outcomes will be assessed before and after the intervention using the SF-12v2 quality of life questionnaire, the Functional Movement Screen (FMS) and the Y-Balance Test. Physical activity levels will be monitored using the IPAQ-SF. The study aims to determine whether lumbar stabilization exercises improve health-related quality of life, motor control and dynamic balance in sedentary adults.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will employ a two-arm parallel randomized controlled design to examine the effectiveness of a four-week lumbar stabilization intervention in sedentary adults. Participants will be randomly allocated in a 1:1 ratio to either an exercise intervention group or a control group.

To enhance measurement reliability, two baseline assessments will be conducted prior to the intervention and two post-intervention assessments will be performed after completion of the program, with a three-day interval between repeated measurements.

The stabilization program will focus on activation and progressive strengthening of the deep trunk musculature, with particular emphasis on transversus abdominis and multifidus activation. Special attention will be given to the acquisition of diaphragmatic breathing patterns to facilitate neuromuscular control. Exercises will be performed in multiple positions, including supine, side-lying, prone, and quadruped positions. The level of difficulty will be progressively increased throughout the four-week intervention period.

The control group will receive written ergonomic education and general stretching instructions without supervised exercise.

Assessments will be conducted using standardized and validated instruments to evaluate motor control, dynamic balance, and health-related quality of life. Statistical analysis will be performed using repeated-measures analysis of variance to assess within-group and between-group differences over time, with a predefined level of statistical significance set at 0.05.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Greece
    • Attica
      • Aigáleo, Attica, Greece, 12243
        • University of West Attica

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy adults with a sedentary lifestyle (no regular structured exercise in the past 2-3 months)

    • Ability to participate in a moderate-intensity exercise program
    • Ability to understand instructions and complete assessment questionnaires

Exclusion Criteria:

  • Regular participation in structured exercise programs within the previous 2-3 months

    • Diagnosed lumbar disc herniation with neurological deficits
    • History of spinal or lower limb surgery within the past year
    • Acute musculoskeletal injury or exacerbation of low back pain within the past 4 weeks
    • Neurological or neuromuscular disorders
    • Active inflammatory rheumatic disease
    • Cardiopulmonary contraindications to moderate-intensity exercise
    • Pregnancy or postpartum period
    • Use of medications significantly affecting balance or physical performance
    • Inability to understand study instructions or comply with study procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Lumbar Stabilization Exercise Group
Structured lumbar stabilization exercise program .
Behavioral: Lumbar Stabilization Exercise Program
A structured four-week lumbar stabilization exercise program targeting deep trunk musculature in healthy sedentary adults. The program will emphasize activation of the transversus abdominis, incorporation of diaphragmatic breathing, and progressive increase in exercise difficulty. Exercises will be performed under supervision in supine, prone, side-lying, and quadruped positions under structured guidance.
Active Comparator: Control Group
Ergonomic advice and general stretching exercise instructions.
Other: Ergonomic and Stretching Instructions
Educational booklet including ergonomic recommendations and general stretching exercises without supervised stabilization training.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Short Form-12 Health Survey (SF-12v2) Scores
Time Frame: Baseline and 4 weeks (post-intervention)
Health-related quality of life will be assessed using the SF-12v2 questionnaire. The eight domain scores (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health) as well as the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores will be calculated. Domain scores will be transformed to a 0-100 scale, with higher scores indicating better perceived health status. PCS and MCS will be computed using norm-based scoring (mean = 50, SD = 10), where higher values reflect better overall physical and mental health.
Baseline and 4 weeks (post-intervention)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Functional Movement Screen (FMS) Total Score
Time Frame: Baseline and 4 weeks (post-intervention)
Motor control will be assessed using the Functional Movement Screen (FMS). Higher scores indicate better motor control and movement quality. The total score ranges from 0 to 21 for the 7 functional test.
Baseline and 4 weeks (post-intervention)
Y-Balance Test Composite Score
Time Frame: Baseline and 4 weeks (post-intervention)

Dynamic balance will be assessed using the Y-balance test. The composite approach distance for each lower limb will be calculated as:

(ANT + PM + PL approach distance) / (3 × limb length) × 100. The composite score is expressed as a percentage of limb length. Minimum value: 0%. Maximum value: 100% (theoretically may exceed 100% in high-performing individuals). Higher values indicate better dynamic balance.

[Time frame: Baseline and 4 weeks (after intervention)] Asymmetry will be calculated as the absolute difference between right and left normalized reach distances (% of limb length).

Minimum value: 0%. No fixed maximum value. Higher values indicate greater asymmetry.
Baseline and 4 weeks (post-intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of West Attica

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Georgios Koumantakis, PhD, University of West Attica

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 25, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 3, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UWestAttica-LSE-116235
  • 116235/12-11-2025 (Other Identifier: Ethics Committee, University of West Attica)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data related to study outcomes and basic demographic characteristics will be made available upon reasonable request and subject to institutional approval.

IPD Sharing Time Frame

Data will be available upon reasonable request after publication of the study results, subject to institutional approval and data protection regulations.

IPD Sharing Access Criteria

Data will be shared with qualified researchers upon reasonable request, following review and approval by the principal investigator and in accordance with applicable data protection regulations.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Lumbar Stabilization Exercise Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings